| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2006 | CA2209775C Analogues of n-acetylardeemin, method of preparation and uses thereof |
| 01/24/2006 | CA2205757C Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| 01/24/2006 | CA2195747C New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments |
| 01/24/2006 | CA2187525C Quinolone derivative for treatment of urinary incontinence |
| 01/24/2006 | CA2186193C Cosmetic compositions containing tricholine citrate |
| 01/24/2006 | CA2186042C Cosmetic or dermopharmaceutical patch containing in an anhydrous polymeric matrice at least one active component, especially unstable in oxidative media, and at least one water absorbing agent |
| 01/24/2006 | CA2166090C Novel process for preparing 17.beta.-substituted 4-azaandrostane derivatives |
| 01/24/2006 | CA2151561C Hydrazino and hydroxyamino-14.beta.-hydroxyandrostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same |
| 01/24/2006 | CA2143864C Morphinan derivatives and pharmaceutical use thereof |
| 01/24/2006 | CA2143419C Novel method for preparing ergothioneine |
| 01/24/2006 | CA2138127C New acyclic amidine group-containing diphosphonic acid derivatives, processes for their preparation and medicaments containing these compounds |
| 01/24/2006 | CA2100228C Phospholipid derivatives |
| 01/23/2006 | CA2586086A1 Furin inhibitors |
| 01/21/2006 | CA2512420A1 Method for filtering blood in a vessel with helical elements |
| 01/20/2006 | CA2512531A1 Use of compounds derived from 2,3-dehydronaringenin for the treatment of inflammatory processes and pharmaceutical composition containing said derivatives |
| 01/19/2006 | WO2006007532A2 2-substituted heteroaryl compounds |
| 01/19/2006 | WO2006007528A2 Lxr/rxr-related methods and compositions |
| 01/19/2006 | WO2006007508A2 Compounds and methods for treating diabetic vascular diseases |
| 01/19/2006 | WO2006007501A2 Mitotic kinesin inhibitors |
| 01/19/2006 | WO2006007497A2 Prodrugs of mitotic kinesin inhibitors |
| 01/19/2006 | WO2006007496A2 Mitotic kinesin inhibitors |
| 01/19/2006 | WO2006007491A1 Mitotic kinesin inhibitors |
| 01/19/2006 | WO2006007436A1 Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
| 01/19/2006 | WO2006007435A1 Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
| 01/19/2006 | WO2006007431A2 Catalyst solution dispenser for a spraying apparatus |
| 01/19/2006 | WO2006007402A2 Poly (lactid acid) copolymer hydrogels and related methods of drug delivery |
| 01/19/2006 | WO2006007398A1 Therapy of platinum-resistant cancer |
| 01/19/2006 | WO2006007392A1 Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| 01/19/2006 | WO2006007384A2 Antibiotics containing borinic acid complexes and methods of use |
| 01/19/2006 | WO2006007378A2 Pyrrolotriazine kinase inhibitors |
| 01/19/2006 | WO2006007358A1 Hypoestoxides, derivatives ans agonists thereof for use as stent-coating agents |
| 01/19/2006 | WO2006007337A1 Vaginal health products |
| 01/19/2006 | WO2006007323A2 Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
| 01/19/2006 | WO2006007312A2 Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation |
| 01/19/2006 | WO2006007310A2 Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids |
| 01/19/2006 | WO2006007261A1 Photo-triggered release of active substances from dendrimer-photosensitizer complexes |
| 01/19/2006 | WO2006007227A2 Abnormal cannabidiols for lowering intraocular pressure |
| 01/19/2006 | WO2006007213A1 Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| 01/19/2006 | WO2006007136A2 Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease |
| 01/19/2006 | WO2006007095A2 High ibuprofen content granules and their preparation and use |
| 01/19/2006 | WO2006006933A2 Antiproliferative compositions comprising aryl substituted xylopyranoside derivatives |
| 01/19/2006 | WO2006006741A1 Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006740A1 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006722A1 Method of controlling cell functions |
| 01/19/2006 | WO2006006691A2 Solid dispersion of a p38 map kinase inhibitor |
| 01/19/2006 | WO2006006616A1 Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same |
| 01/19/2006 | WO2006006595A1 Medicinal composition for oral use |
| 01/19/2006 | WO2006006577A1 Loxoprofen-containing composition for oral administration |
| 01/19/2006 | WO2006006021A2 Stabilized pharmaceutical compositions of preferably a statin |
| 01/19/2006 | WO2006005955A1 Amide derivatives as inhibitors of histone deacetylase |
| 01/19/2006 | WO2006005924A1 Porphyrin derivatives and their use in photon activation therapy |
| 01/19/2006 | WO2006005856A1 Use of polyphenol ethylene organometallic derivatives for treating a non-hormone dependent cancer |
| 01/19/2006 | WO2006005853A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 01/19/2006 | WO2006005845A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 01/19/2006 | WO2006005844A1 Pressurized foaming composition for topical treatment of psoriasis |
| 01/19/2006 | WO2006005843A1 Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology |
| 01/19/2006 | WO2006005842A1 Pharmaceutical composition comprising an ointment and two solubilized active principles |
| 01/19/2006 | WO2006005760A1 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
| 01/19/2006 | WO2006005741A2 Piperdine derivatives as renin inhibitors |
| 01/19/2006 | WO2006005726A2 Heterocyclic compounds |
| 01/19/2006 | WO2006005633A1 Combinations of pure anti-estrogen with aromatase inhibitors |
| 01/19/2006 | WO2006005631A1 Use of phenylethanolaminotetralines for preparing anxiolytic drugs |
| 01/19/2006 | WO2006005613A1 Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors |
| 01/19/2006 | WO2006005602A2 Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| 01/19/2006 | WO2006005548A1 Novel 2,6-diaminopyridine-3-one derivatives |
| 01/19/2006 | WO2006005512A1 Granules for controlled release of tamsulosin |
| 01/19/2006 | WO2006005486A1 Sulfonamide derivatives |
| 01/19/2006 | WO2006005463A1 Cosmetic and/or pharmaceutical compositions containing fatty acids and extracts of castaneva sativa |
| 01/19/2006 | WO2006005415A2 Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
| 01/19/2006 | WO2005117890A3 Thienopyrimidines and thiazolopyrimidines for use in medicine |
| 01/19/2006 | WO2005116088A3 Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| 01/19/2006 | WO2005113514A3 Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems |
| 01/19/2006 | WO2005110423A3 Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias |
| 01/19/2006 | WO2005107807A3 Cerebral intraventricular transplantation as method of treating amyotrophic lateral sclerosis |
| 01/19/2006 | WO2005107757A3 A method for the prevention of thromboembolic disorders |
| 01/19/2006 | WO2005105805A9 Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production thereof |
| 01/19/2006 | WO2005105785A3 Indole derivatives for treatment of obesity |
| 01/19/2006 | WO2005102307A3 Beneficial effects of increasing local blood flow |
| 01/19/2006 | WO2005099705A3 Preparation of imidazole derivatives and methods of use |
| 01/19/2006 | WO2005097129A3 6-azaindole compound |
| 01/19/2006 | WO2005095357A3 Pyrimidine derivatives and methods of treatment related to the use thereof |
| 01/19/2006 | WO2005094218A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| 01/19/2006 | WO2005092307A3 Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists |
| 01/19/2006 | WO2005082379A8 Myocardial perfusion imaging using adenosine receptor agonists |
| 01/19/2006 | WO2005082341A3 NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF |
| 01/19/2006 | WO2005080366A8 Alkyl carbamate-substituted butyrolactones serving as lipase inhibitors |
| 01/19/2006 | WO2005074913A3 Compositions and methods for treating contracture |
| 01/19/2006 | WO2005070930A3 Tetrahydrocarboline compounds as anticancer agents |
| 01/19/2006 | WO2005065317A3 Effervescent oral fentanyl dosage form |
| 01/19/2006 | WO2005054436A3 Compositions and methods for preservation of vascular grafts |
| 01/19/2006 | WO2005042514A3 Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound |
| 01/19/2006 | WO2005037317A3 Mast cell-derived renin |
| 01/19/2006 | WO2005000291A8 Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives |
| 01/19/2006 | US20060015077 Transdermal patches having a siliconic adhesive matrix stabilized with methacrylic copolymers |
| 01/19/2006 | US20060015054 External plaster containing 4-biphenylacetic acid |
| 01/19/2006 | US20060014982 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
| 01/19/2006 | US20060014978 Mixed esters of dicarboxylic acids for use as pigment dispersants |
| 01/19/2006 | US20060014963 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/19/2006 | US20060014962 Thiadiazole compound and use thereof |
| 01/19/2006 | US20060014953 7-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5- alpha ]pyrazine, hydrochloride; antidiabetic agent, non-insulin dependent diabetes; synergistic mixture with other active ingredients |